8-K: CEL-SCI Secures $5.7 Million Through Common Stock Offering to Advance Multikine Development

CEL-SCI Corporation, a clinical-stage cancer immunotherapy company, successfully closed a best-efforts offering of 1.5 million common shares, raising approximately $5.7 million in gross proceeds to fund the continued development of its lead product, Multikine, and for general corporate purposes.

Summary

• CEL-SCI Corporation completed a best-efforts offering of 1,500,000 shares of its common stock.
• The shares were sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules.
• The offering generated approximately $5,730,000 in gross proceeds before deducting placement agent fees and other offering expenses.
• Net proceeds from the offering are intended to fund the continued development of Multikine, for general corporate purposes, and working capital.
• ThinkEquity LLC acted as the sole placement agent for the offering, receiving a cash fee equal to 7.0% of the gross proceeds and reimbursement for certain expenses up to $95,000.
• The company is subject to a 30-day lock-up period from July 11, 2025, restricting new equity issuance, with certain exceptions.
• Directors and officers are subject to a 45-day lock-up period from July 11, 2025, restricting the sale or transfer of company securities they hold, with certain exceptions.

Sentiment

Score: 7

Explanation: The successful completion of a capital raise, while dilutive, is a positive and necessary step for a clinical-stage biotechnology company like CEL-SCI, ensuring continued funding for its lead product development and operations. The 'at-the-market' pricing and the specific allocation of funds to Multikine development are favorable aspects, despite the associated costs and dilution.

Positives

• Successfully raised approximately $5.7 million in gross proceeds, providing capital for ongoing operations and Multikine development.
• The offering was priced 'at-the-market,' indicating a market-based valuation for the shares.
• Secured funding for the continued development of Multikine, a clinical-stage cancer immunotherapy with Orphan Drug designation from the FDA for head and neck squamous cell carcinoma.
• The company maintains its listing on NYSE American, with the newly issued shares approved for listing.

Negatives

• The issuance of 1,500,000 new shares will result in dilution for existing shareholders.
• The company incurred placement agent fees of 7.0% of gross proceeds and up to $95,000 in expense reimbursements, reducing net proceeds.
• The company and its insiders are subject to lock-up periods, which could temporarily restrict liquidity for certain shareholders and the company's ability to raise further capital through equity issuance.

Risks

• Inability to duplicate clinical results demonstrated in clinical studies.
• Inability to timely develop any potential products that can be shown to be safe and effective.
• Failure to receive necessary regulatory approvals for potential products.
• Difficulties in manufacturing any of the company's potential products.
• Inability to raise necessary capital in the future.
• General risks and uncertainties faced by the company as detailed in its prospectus supplement filed on July 11, 2025, and its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.

Future Outlook

The company intends to use the net proceeds from the offering to fund the continued development of Multikine, for general corporate purposes, and working capital. Future success is subject to risks including the ability to duplicate clinical results, timely development of safe and effective products, obtaining regulatory approvals, manufacturing capabilities, and the ability to raise necessary capital.

Management Comments

• CEL-SCI believes that boosting a patient's immune system before surgery, radiotherapy, and chemotherapy have damaged it, should provide the greatest possible impact on survival.
• Multikine is designed to help the immune system 'target' the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

Industry Context

This capital raise by CEL-SCI is typical for a clinical-stage biotechnology company, which often relies on equity financing to fund extensive and costly research and development, particularly for drug candidates like Multikine. The 'best-efforts' nature of the offering is common for smaller biotechs, indicating that the placement agent will use its best efforts to sell the shares but is not obligated to purchase any unsold shares. The focus on Multikine, a cancer immunotherapy, aligns with a significant trend in the pharmaceutical industry towards developing novel treatments that leverage the body's immune system to fight cancer.

Comparison to Industry Standards

• The 'best-efforts' offering structure is a common method for smaller, clinical-stage biotechnology companies to raise capital, as it shifts the risk of unsold shares from the underwriter to the issuer, unlike a 'firm commitment' offering which is more typical for larger, more established companies.
• A 7.0% placement agent fee is within the typical range for best-efforts offerings, which can vary from 5% to 10% depending on the size of the offering and the perceived risk.
• The use of proceeds for 'continued development of Multikine, general corporate purposes, and working capital' is standard for a biotech company, reflecting the high capital requirements for clinical trials and operational overhead.
• The lock-up periods for the company (30 days) and insiders (45 days) are shorter than typical IPO lock-ups (often 90-180 days) but are common for follow-on offerings, aiming to prevent immediate downward pressure on the stock price post-offering.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of new shares, but benefit from the company's enhanced financial stability and ability to fund Multikine development.
• Employees: Benefit from the continued funding of operations, which supports job security and ongoing research efforts.
• Customers/Patients: Potential long-term benefit from the continued development of Multikine, which aims to provide a new cancer immunotherapy treatment.
• Creditors: Improved financial position may reduce credit risk, as the company has secured additional working capital.

Next Steps

• Continued development of Multikine.
• Company to maintain registration of common stock under the Exchange Act for at least three years.
• Company to maintain listing of common stock on NYSE American for at least three years.
• Company to furnish periodic and special reports to the Placement Agent for three years.
• Company to make an earnings statement generally available to security holders within 15 months covering a 12-month period after the agreement date.

Key Dates

Recommendation

Keywords

CEL-SCI Corporation, CVM, Common Stock Offering, Capital Raise, Equity Offering, Multikine, Cancer Immunotherapy, Clinical Stage, Biotechnology, SEC Filing, 8-K, ThinkEquity, NYSE American, Orphan Drug, Squamous Cell Carcinoma, Head and Neck Cancer